Equities analysts predict that NuCana plc (NASDAQ:NCNA – Get Rating) will post earnings of ($0.19) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for NuCana’s earnings. The highest EPS estimate is ($0.12) and the lowest is ($0.22). NuCana posted earnings per share of ($0.26) during the same quarter last year, which suggests a positive year over year growth rate of 26.9%. The business is scheduled to report its next earnings report on Monday, January 1st.
Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for NuCana.
NCNA opened at $0.66 on Monday. The company has a market capitalization of $34.18 million, a PE ratio of -0.62 and a beta of 0.58. The company’s 50 day simple moving average is $0.99. NuCana has a one year low of $0.61 and a one year high of $3.85.
A number of institutional investors have recently bought and sold shares of the business. Moors & Cabot Inc. acquired a new stake in shares of NuCana in the 3rd quarter worth $245,000. Wells Fargo & Company MN boosted its position in shares of NuCana by 186.6% in the 2nd quarter. Wells Fargo & Company MN now owns 13,055 shares of the company’s stock worth $36,000 after purchasing an additional 8,500 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of NuCana in the 4th quarter worth $33,000. Virtu Financial LLC acquired a new stake in shares of NuCana in the 4th quarter worth $69,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of NuCana by 191.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 50,952 shares of the company’s stock worth $121,000 after purchasing an additional 33,497 shares in the last quarter. Institutional investors own 51.49% of the company’s stock.
NuCana Company Profile (Get Rating)
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase III clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with metastatic pancreatic cancer.
- Get a free copy of the StockNews.com research report on NuCana (NCNA)
- ChemoCentryx: A Biotech Stock Well Worth the Risk
- Skechers Stock Can Be Bought on Pullbacks
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.